Phase
Condition
Crohn's Disease (Pediatric)
Treatment
Placebo
Rosuvastatin
Clinical Study ID
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Established diagnosis of stricturing Crohn's disease
Scheduled for surgical resection of terminal ileum strictures at either
Stanford University, or
Dr. Phillip Fleshner's colorectal surgery practice in Los Angeles
Exclusion
Exclusion Criteria:
Pregnant, nursing, or planning to become pregnant in the next 6-12 months
Severe renal dysfunction (stage 5 chronic kidney disease (CKD), end-stage renaldisease (ESRD))
Known clinical allergy or prior adverse reaction to statin therapy (e.g.,rhabdomyolysis)
Current use of cyclosporine
Current use of statin therapy prior to study initiation
Clinical diagnosis of active liver disease (beyond metabolic dysfunction-associatedsteatotic liver disease (MASLD)) with unexplained persistent elevations in hepatictransaminase levels
Current use of any of the following medications, without explicit clearance from atreating physician to enroll in the study:
Antifungals (e.g., ketoconazole, itraconazole, voriconazole)
Fibrate drugs
Macrolide antibiotics (e.g., erythromycin, clarithromycin)
Protease inhibitors (e.g., ritonavir, lopinavir)
Calcium channel blockers (e.g., verapamil, diltiazem)
Amiodarone
Warfarin
Colchicine
Study Design
Study Description
Connect with a study center
Stanford University
Stanford, California 94305
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.